Pembrolizumab in mycosis fungoides with PD-L1 structural variants

Blood Adv. 2021 Feb 9;5(3):771-774. doi: 10.1182/bloodadvances.2020002371.

Abstract

  1. PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation.

  2. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • B7-H1 Antigen
  • Humans
  • Mycosis Fungoides* / drug therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • CD274 protein, human
  • pembrolizumab